# Biocon Sdn. Bhd. (Company No. 201101002193) – FDA 483, Feb 15, 2018

Source: https://www.keypedia.com/records/483/biocon-sdn-bhd-company-no-201101002193/df3b519f-0669-48ed-a8cd-bc3c435a6309

> FDA 483 for Biocon Sdn. Bhd. (Company No. 201101002193) on February 15, 2018. Product: Drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Biocon Sdn. Bhd. (Company No. 201101002193)
- Inspection Date: 2018-02-15
- Product Type: Drugs
- Office Name: Center for Drug Evaluation and Research
- Summary: This FDA Form 483 details observations from an inspection of a facility manufacturing sterile drug products.

**Key Violations and Observations:**

1.  **Inadequate Microbiological Contamination Prevention:**
    *   **Process Simulation Studies (Media Fills) Deficiencies:**
        *   Rejected stoppered vials with seal defects (e.g., 846, 2,007, 1,310, 504, 139 units in various batches) were not incubated, contrary to control procedure BM/QA/SOP/019 Section 6.1.5, which states units with integrity defects should not be considered part of incubation. This practice is deemed insufficient, especially for multi-dose products.
        *   Media fills for the REDACTED Filling Machine (03-02 REDACTED) do not accurately represent routine aseptic filling conditions. The frequency and duration of simulated operator interventions are not based on thorough historical or retrospective data evaluation.

2.  **Inadequate Re-qualification of REDACTED Filling Machine (03-02 REDACTED):**
    *   **REDACTED Re-qualification (Report BM/PDP/RQ/P/050-02, 02/04/2018):** Acceptance criteria for integrity, filling volume, and seal integrity were based only on "GOOD" units post-1

## Related Documents

- [483 - 2024-09-27](https://www.keypedia.com/records/483/biocon-sdn-bhd-company-no-201101002193/70fdd8a0-8724-4a60-b1f7-de8e766bbc9d) — date: September 27, 2024
- [483 - 2023-07-20](https://www.keypedia.com/records/483/biocon-sdn-bhd-company-no-201101002193/a1b1d4cf-8a75-42f3-b146-485dbfc22819) — date: July 20, 2023
- [483 - 2022-08-30](https://www.keypedia.com/records/483/biocon-sdn-bhd-company-no-201101002193/15e77f60-928f-4501-b721-30527651609a) — date: August 30, 2022
- [483 - 2021-09-24](https://www.keypedia.com/records/483/biocon-sdn-bhd-company-no-201101002193/9e2101ef-395a-4fb1-8d8b-f40f12e1446d) — date: September 24, 2021
- [483 - 2020-02-21](https://www.keypedia.com/records/483/biocon-sdn-bhd-company-no-201101002193/a0f8c894-0375-4456-8e4a-381835759c81) — date: February 21, 2020

## Related Officers

- [Quality System Specialist](https://www.keypedia.com/people/jose-e-melendez/75bd6083-14a4-4bd2-a0e5-9946d4dd37e1)
- [Investigator](https://www.keypedia.com/people/roger-f-zabinski/87e05838-f8b5-489a-8db7-6669e68a2c2e)

Company: https://www.keypedia.com/companies/biocon-sdn-bhd-company-no-201101002193/b7eb03f4-676c-44c0-af88-528fbc4236a8

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c